Thermo’s Watson LIMS has been integrated with Symyx’ electronic lab notebook.

Thermo Fisher Scientific reports that it has successfully integrated its Watson LIMS (laboratory information management system) with Symyx Technologies’ electronic lab notebook (ELN). This solution is intended to provide scientists in the bioanalytical community with a completely electronic, automated laboratory workflow. 

The integrated product enables scientists to drive their existing workflow in Watson LIMS while also performing sample preparation, managing instrument calibration and maintenance, and completing the experimental record in the Symyx Notebook, all under GLP compliance. The solution also ensures that all experimental details on projects or studies are authenticated by Watson and documented electronically, allowing scientists to share reports and results with colleagues across the lab or in another location, the companies add.

“Today, pharmaceutical companies are looking for efficiencies in workflow, and by guiding the laboratory users through their study protocols and bioanalytical assays in the LIMS and ELN, we have enabled scientists to maximize not only their workflow but also their knowledge while saving time and eliminating manual transcription errors,” says Dave Champagne, vp and GM for Thermo Fisher Scientific. “The integration of Watson LIMS with Symyx Notebook provides electronic access to all of the data generated—whether it’s structured data stored in the LIMS or unstructured data stored in the ELN.”

Thermo Scientific Watson LIMS is a specialized, protocol-driven LIMS for drug metabolism and pharmacokinetic studies. Symyx Notebook is a single, multidisciplinary ELN that helps speed R&D productivity, improve collaboration, and streamline regulatory compliance. The integration of these technologies is based on a partnership between the companies that was inked in March.

Previous articleScripps-Led Consortium that Combines Physics and Oncology Receives $10M
Next articlePPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics